Spain’s largest drugmaker Almirall (ALM: MC) has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe from USA-based Dermira (Nasdaq: DERM).
Almirall and Dermira previously entered into an option and license agreement in February 2019 under which Almirall was granted this exclusive option in exchange for an upfront option fee of $30 million. As a result of Almirall's decision, the company will pay Dermira $50 million and Dermira will be eligible to receive additional payments upon the achievement of certain milestones, including $30 million in connection with the initiation of certain Phase III clinical studies.
Almirall’s shares edged up 1.6% to 15.74 euros by late afternoon, while Dermira was up 3.26% at $9.82 in mid-morning Nasdaq trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze